Multiple buying at ImmunoVaccine (IMV)

Multiple buying at ImmunoVaccine (T:IMV)

Pierre Labbé, a Senior Officer, acquired 50,000 Common Shares on a direct ownership basis at a price of $1.300 through a prospectus or prospectus exempt offering on June 21st, 2017. This represents a $65,000 investment into the company's shares and an account share holdings change of 30.6%.

On the same terms, Andrew J. Sheldon, a Director, acquired 10,000 Common Shares on an indirect ownership basis for registered holder RRSP and 30,000 Common Shares on an indirect ownership basis for registered holder TFSA. This represents a $52,000 investment into the company's shares and an account share holdings change of greater than 100%. Frederic Ors, CEO and Director, acquired 8,000 Common Shares on a direct ownership basis. This represents a $10,400 investment into the company's shares and an account share holdings change of 2.7%.

Finally, James Willis Hall, a Director, acquired 7,700 Common Shares on a direct ownership basis. This represents a $10,010 investment into the company's shares and an account share holdings change of 6.5%.

ImmunoVaccine is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Immunovaccine Inc. is a clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.